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Abstract Invasive breast cancer represents the endpoint of
a developmental process that originates in the terminal duct
lobular units and is believed to progress through stages of
increasing proliferation, atypical hyperplasia, and carcino-
ma in situ before the cancer acquires invasive and
metastatic capabilities. By comparison with invasive breast
cancer, which has been studied extensively, the preceding
stages of benign breast disease are more poorly understood.
Much less is known about the molecular changes underly-
ing benign breast disease development and progression, as
well as the transition from in situ into invasive disease.
Even less focus has been given to the specific role of
stroma in this progression. The reasons for lack of
knowledge about these lesions often come from their small
size and limited sample availability. More challenges are
posed by limitations of the models used to investigate the
lesions preceding invasive breast cancer. However, recent
studies have identified alterations in stromal cell function
that may be critical for disease progression from benign
disease to invasive cancer: key functions of myoepithelial
cells that maintain tissue structure are lost, while tissue
fibroblasts become activated to produce proteases that
degrade the extracellular matrix and trigger the invasive
cellular phenotype. Gene expression profiling of stromal
alterations associated with disease progression has also
identified key transcriptional changes that occur early in
disease development. In this review, we will summarize
recent studies showing how stromal factors can facilitate
progression of ductal carcinoma in situ to invasive disease.
We also suggest approaches to identify processes that
control earlier stages of disease progression.
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The human breast consists of a branched parenchymal
network that produces milk during lactation and drains it to
t h en i p p l e[ 1]. The milk-producing structures of the
mammary gland are collections of multiple small acini at
the distal ends of the ducts, and are known as terminal duct
lobular units (TDLU) (Fig. 1a). Although many of the exact
mechanisms and mediators underlying the development of
human breast cancer remain unknown, the most commonly
hypothesized model posits that invasive breast cancer
initiates from the TDLU and progresses through stages of
benign breast disease (BBD) in incremental steps of
increasing cellular abnormalities marked by excessive
proliferation and atypia [1–4] (Fig. 1b). According to this
model, abnormal proliferation in TDLU initially leads to
unfolded lobules and/or cystic structures (Fig. 1c a), which
progress through stages where the epithelium becomes
increasingly proliferative without acquiring atypical char-
acteristics (proliferative disease without atypia, PDWA,
Fig. 1c b–d). Atypical hyperplasia can manifest as either
ductal or lobular forms (atypical ductal hyperplasia [ADH]
or atypical lobular hyperplasia [ALH], respectively, Fig. 1c
e, f), as can the early stages of carcinoma in situ
(characterized as ductal carcinoma in situ [DCIS, Fig. 1c
g] and lobular carcinoma in situ [LCIS]).
Multiple epidemiologic studies provide evidence sup-
porting this model in which invasive breast cancer
develops from benign disease [5–8]. Common genetic
and epigenetic alterations have been identified in PDWA,
atypia, DCIS and invasive breast cancer, often occurring
progressively along this stepwise pathway [3, 4, 9, 10],
with extensive similarities observed in gene expression
profiles across atypia, DCIS and invasive cancer in the
same breast [9]. Furthermore, the lifetime risk of subse-
quently developing invasive breast cancer (relative risk,
RR) increases in a progressive fashion according to the
histological subtype of benign disease: women with
PDWA have RR of 1.3–1.9 [6–8] ,w o m e nw i t ha t y p i c a l
hyperplasia have RR of 3.5–5.3 [6–8, 11], and women
with DCIS have RR of 10–11 [1]. It should be emphasized
however, that although benign breast disease is associated
with significantly increased risk for subsequent disease
progression, only a small proportion of benign disease
lesions will actually develop into invasive cancer. Given
the critical role of stroma in breast development and in
transition from localized breast cancer to invasive disease
[12], it is likely that the stromal microenvironment is also
involved in progression of benign disease to carcinoma. In
this review, we will describe the characteristics of benign
disease progression, evaluate the potential contribution of
microenvironmental signals to the progression of benign
disease to invasive cancer, and examine recent studies that
identify microenvironmental alterations in premalignant
disease. We propose that a better understanding of the
specific features of the stromal microenvironment that
contribute to progression of benign disease to invasive
cancer will yield new prognostic markers better identify-
ing those women at greatest risk for subsequent develop-
ment of invasive cancer, will improve early detection of
disease, and will identify novel points for therapeutic
intervention to reduce disease incidence.
Modeling Progression from Benign Disease to Invasive
Cancer
The best investigated benign breast lesions are ALH, ADH,
and DCIS [1]. It should be noted that the terminology
“ductal” and “lobular” used to define distinct breast lesions
does not imply the site of origin within the mammary gland
or the types of cells from which it is likely to have formed;
rather the classification is based on the discrete architecture,
cytology and immunohistochemistry (IHC) of the lesion.
Moreover, the vast majority of mammary tumors and their
precursors, independent of their histological type, are
believed to originate from TDLUs and not, as previously
believed, from other microanatomical sites of the normal
breast [13–15]. However, as the ductal type lesions
encompass almost 80% of all diagnosed breast cancers
Figure 1 Pathological characteristics associated with breast cancer
progression. a Normal terminal duct lobular unit (TDLU), the
anatomic substructure from which breast cancer originates, containing
numerous individual acini and surrounded by interlobular stroma. b
Model of progression from normal epithelium through benign breast
disease to invasive breast cancer, indicating relative lifetime risk for
cancer development as compared to women with no proliferative
disease. Women with proliferative disease without atypia (PDWA)
have an increased relative risk (RR) of 1.3–1.9; women with atypical
hyperplasia (atypia) have RR of 3.5–5 . 3 ;w o m e nw i t hd u c t a l
carcinoma in situ (DCIS) have RR of 10–11. c Stages of progression
from benign breast disease to invasive, metastatic breast cancer. a
Nonproliferative disease depicting mammary cysts, fluid-filled struc-
tures derived from TDLU. b Proliferative disease without atypia
(PDWA): adenosis, a proliferative lesion characterized by increased
number or size of glandular structures. c PDWA: moderate hyperpla-
sia, characterized by an increased number of epithelial cells in breast
ducts and lobules with 5 or more cells above the basement membrane,
often with bridging of the luminal space. d PDWA: florid hyperplasia,
in which hyperplastic cells with unevenly distributed nuclei proliferate
in solid clusters distending the lumens and often leading to their
complete closing and loss. e Atypical ductal hyperplasia, epithelial
hyperplasia with bridging architecture and monotonous cytologic
features suggesting expansion of a cell population. f Atypical lobular
hyperplasia characterized by enlarged lobules partially involved with
acini expanded with monotonous dyshesive epithelial cells. g Ductal
carcinoma in situ, a malignant proliferation of epithelial cells
remaining within the basement membrane; some surrounding inflam-
matory infiltrate is seen. h Invasive breast cancer- malignant cells have
invaded the surrounding stromal tissues. i Lymph node metastasis
b
390 J Mammary Gland Biol Neoplasia (2010) 15:389–397worldwide [16], the majority of investigations of genetic
and molecular changes in breast cancer development and
progression are based on this type of preinvasive and
invasive tumor; accordingly, we will focus here on
discussion of ductal-type lesions.
ADH lesions are derived from outgrowths of luminal
epithelial cells and are morphologically related to low-
grade DCIS [1, 4, 17], with the distinction based on the
degree of occupied space. The proliferating cells become
monomorphic with similar-sized nuclei and few mitotic
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J Mammary Gland Biol Neoplasia (2010) 15:389–397 391figures [5]. The average proliferation rate in normal TDLUs
is about 2%, whereas it increases to 5% in ADH and 15%
in DCIS [4]. DCIS is a group of preinvasive cancerous
lesions that arise as a result of neoplastic proliferation of
luminal epithelial cells that do not cross the basement
membrane (BM) [1]. Traditionally, the transition from
DCIS to invasive carcinoma is considered to involve
disruption of the BM and the surrounding layer of
myoepithelial cells (Fig. 2). However, the Sontag-Axerold
model proposes a different pathway in which both DCIS and
invasive cancer originate from a common progenitor cell [18,
19]. Both DCIS and invasive cancer are histologically and
biologically diverse, composed of many different subtypes
[2]; in high grade DCIS the myoepithelial cell layer and the
BM become discontinuous, with proliferation of fibroblasts,
increased angiogenesis, and infiltration of lymphocytes [20–
22]. It may be that well-differentiated DCIS gives rise to low
grade invasive cancer, whereas poorly-differentiated DCIS
evolves through a distinct pathway, progressing into high
grade invasive cancer [23]. Alternatively, it may be that
atypia (or perhaps even an earlier proliferative lesion) may
represent the key step from which cancer develops. In
support of this possibility, biopsies of breast tissue removed
prophylactically from BRCA1/2 carriers were found to
contain various proliferative benign lesions including atypia
in over 50% of cases [24, 25]. Moreover, PDWA and atypia
are frequently found in random periareolar fine needle
aspirations from high risk women compared to normal risk
women [26]. If DCIS represents a symptom of a propensity
to develop invasive cancer, rather than an obligate precursor,
then it becomes paramount to define which benign lesions
a r et r u ep r e c u r s o r so fi n v a s i v ec a n c e r ,a n dt oi d e n t i f yt h e
signals that drive disease progression.
Microenvironmental Components that Drive
Progression from Benign Disease to Invasive Cancer
Myoepithelial Cells In the nonmalignant mammary gland,
myoepithelial cells surround luminal and alveolar epithelial
cells of the mammary duct lobular network, separating the
luminal cells from the basement membrane, and playing
key roles in mammary gland development and reorganiza-
tion [27, 28]. They help regulate luminal cell polarity,
ductal morphogenesis, produce basement membrane com-
ponents and aid milk ejection during lactation. One of the
key characteristics of progression to invasive cancer is
alteration in and loss of the myoepithelial cells. Even
though the myopeithelial cell layer remains intact in DCIS,
the myoepithelial cells themselves differ substantially from
those found in normal tissue: DCIS-associated myoepithe-
lial cells have decreased expression of genes involved in
normal cell function, including thrombospondin, laminin,
and oxytocin receptor, and increased expression of genes
that drive increased proliferation, migration, invasion and
angiogenesis, including CXCL12 and CXCL14 [29].
Phenotypic alterations of myoepithelial cells, as evidenced
by decreased staining for myopeithelial specific markers,
were also found in an IHC study that compared DCIS cases
to normal tissue [30]. Therefore, even if the myoepeithelial
cell layer remains intact in DCIS, the cells themselves may
have already acquired changes that facilitate tumorigenic
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Figure 2 Stromal alterations in breast cancer progression. a In
phenotypically normal tissue, epithelial structures consist of central
luminal epithelial cells encircled by myoepithelial cells and enclosed
by a continuous basement membrane, while the primarily collagenous
stroma contains fibroblasts, immune cells, and vasculature. b
Progression to carcinoma in situ is characterized by proliferative
epithelial cells enclosed in a still-continuous basement membrane,
increased numbers of fibroblasts and immune cell infiltrate, and
enhanced angiogenesis. c Invasive breast carcinoma is defined by
breakdown of the basement membrane, loss of myoepithelial cells,
and invasion of the tumor cells into the surrounding stroma and the
vasculature
392 J Mammary Gland Biol Neoplasia (2010) 15:389–397progression of the luminal epithelial cells. It may be
possible to design therapeutic approaches to counter the
tumor potentiating activities of altered myoepithelial cells.
Experimental mouse models of progression from DCIS to
invasive cancer using the MCF10DCIS.com human cell
line revealed that co-injection of human fibroblasts, either
from normal tissue or invasive cancer, promoted progres-
sion into invasive carcinoma, whereas additional injection
of normal human myoepithelial cells overcame this tumor-
promoting effect [31]. This may be due in part to a loss of
the tumor suppressing characteristics of normal myoepithe-
lial cells. Normal myoepithelial cells secrete maspin and
other proteinase inhibitors that suppress cancer cell prolif-
eration and invasion [27, 32, 33], while tumor myoepithe-
lial cells produce matrix metalloproteinases (MMPs) and
cathepsins that degrade the basement membrane and
facilitate tumor cell invasion [34]. Tumor myoepithelial
cells are deficient for production of laminin-1, a critical
component of the basement membrane, which as a result
renders them unable to aid polarization and organized
growth of mammary epithelial cells [35].
Fibroblasts Fibroblasts are key players in the maintenance
of normal tissue structure and in the progression to
malignancy [36]. Early experiments revealed that
carcinoma-associated fibroblasts (CAFs) can promote tu-
morigenic conversion of initiated epithelial cells, while
fibroblasts derived from normal tissue suppress this
transition [37]. Hu et al. have previously shown that
fibroblasts promote, and myoepithelial cells suppress,
progression form DCIS to invasive cancer in a mouse
xenograft model [31]. Subsequent investigations provided
information about the key signals from CAFs that drive
tumor progression. A study using a co-implantation
xenograft model revealed that secretion of CXCL12 by
CAFs promoted angiogenesis and increased cancer cell
proliferation through interaction with CXCR4 expressed by
tumor cells [38]. A separate study with a similar design
revealed that coimplantation of CAFs with MCFDCIS cells
leads to activation of COX-2, a mediator of inflammation
that is a negative prognostic indicator in invasive cancer
[39, 40]. Inhibition of COX-2 completely blocked the
increased growth of tumors with co-injected fibroblasts and
inhibited transition from DCIS to invasive cancer. These
studies indicate a critical role for fibroblast activation and
accumulation in breast cancer progression.
ECM-degrading Proteinases Loss of the basement mem-
brane is one of the key steps in the transition from DCIS to
invasive cancer. Matrix metalloproteinases (MMPs) are
proteolytic enzymes able to degrade nearly all the compo-
nents of the basement membrane, as well as to activate
growth factors, degrade cell-cell and cell-ECM adhesion
molecules, and activate zymogen forms of other MMPs [41,
42]. DCIS has been found to have higher expression of
MMP-2 and MMP-9 when compared to normal and
hyperplastic tissue [43]. Other studies have observed
MMP-1, -2, -3, -9, and -11 in the stroma around preinvasive
lesions [23, 44–46]. The expression of heparanase-1,
another matrix degrading enzyme able to degrade heparin
sulfate proteoglycans, has been found to correlate with
higher grade in situ tumors, suggesting its role in
progression from DCIS into invasive cancer [47]. Analysis
of stromal protease expression by transcriptional profiling
of DCIS and invasive cancer using laser capture microdis-
section (LCM, Fig. 3) identified matrix related genes,
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Figure 3 Transcriptional profiling of stromal alterations. Slides from
breast tissue biopsies are microdissected to separate the proliferative
epithelial cells from the surrounding stroma. RNA is extracted from
the tissue slides and analyzed by microarray; comparison of
transcriptional profiles from patients who subsequently progressed to
invasive breast cancer with profiles from patients who did not progress
can reveal transcripts prognostic for breast cancer progression
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tor (PLAU), among stromal genes upregulated in invasive
cancer [46]; increased expression of MMP1 and MMP12
expression in the stroma has also been associated with poor
prognosis for patients with invasive cancer [48]. Such studies
provide insight into which MMPs and other matrix-
degrading proteinases may be potentially useful therapeutic
targets. However, increased selectivity of any new candidate
proteinase inhibitors will be important in order to avoid the
problems of previous clinical trials in which broad-spectrum
MMP inhibitors performed very poorly in patients with
advanced disease due to adverse side effects [49].
Transcriptional Dissection of Stromal Contribution
to Breast Cancer Progression
Development of new methodologies for separation of breast
stroma from the epithelial lesions by LCM (Fig. 3)o rb y
sorting of cells on the basis of surface markers, combined
with transcriptional profiling to identify patterns of gene
expression differences, has provided substantial new infor-
mation about stromal signals that control breast cancer
progression. A recent study by Finak et al. [48]u s e dI B C
tissue biopsies and matched uninvolved tissue from patients
for which clinical outcome data were available. LCM-
isolated IBC tumor stroma and matched normal stroma were
subjected to microarray profiling, and the results were used
to derive a prognostic predictor gene set that could be
validated using separate profiling data and that was shown to
predict outcome prior to detectable metastasis [48]. Another
study in which both tumor and stroma from IBC patients
were analyzed for transcriptional profiles of genes encoding
ECM and ECM-modifying proteins identified a good
prognosis gene set which showed increased expression of
serine protease inhibitors, and a poor prognosis set, which
showed upregulation of integrins and MMPs and down-
regulation of laminins [50].
Another LCM/microarray-based study comparing ex-
pression profiles of epithelium and stroma from IBC and
matched adjacent normal tissue found that gene signatures
from uninvolved normal epithelium and stroma were not
predictive of tumor outcome, and also that the uninvolved
epithelial and stromal tissue was not substantially different
from expression profiles of epithelial and stromal tissue
derived from reduction mammoplasty [51]. The results of
this study suggest that stromal effects on tumor progression
are likely to be specific to the tumor microenvironment
rather than systemic alterations.
Profiling of tumors derived from the stroma has also
provided insight into the role of stroma in the progression
to IBC. Two types of fibroblastic tumors, solitary fibrous
tumor (SFT) and desmoid-type fibromatosis (DTF), have
been investigated by transcriptional profiling, and gene sets
which differentiated normal from SFT or DTF were also
found to be predictive of outcome for IBC [52]. When
profiles of IBC biopsies (obtained from samples containing
both stroma and epithelial tissue) were grouped by similar
gene expression, one subgroup of IBC patients showed
significantly elevated expression of genes that were
associated with DTF, the majority of which were involved
in a pro-fibrotic ECM interaction or stimulation (e.g.,
collagens, MMPs, transforming growth factor-β,a n d
myofibroblast-associated genes). This set was termed a
fibrotic stromal response group and corresponded with
lower tumor grade, increased estrogen receptor expression,
and better survival prognosis [52, 53]. A distinct IBC
subgroup was found to be associated with SFT-associated
transcriptional alterations, mostly ECM/basement mem-
brane specific genes, and was correlated with poor
prognosis. A third type of stromal response signature,
designated a macrophage/colony stimulating factor-1 (CSF-
1) signature, also showed relevance to breast cancer subsets
[54]. These were higher grade tumors, progesterone and
estrogen receptor negative, and positive for TP53 muta-
tions, with survival prognosis varying between the cancer
subsets. The fibroblast (DTF) and macrophage (CSF1)
stromal response signatures were also found in specific
subsets of DCIS, as identified by both gene expression and
IHC [55]. Interestingly the macrophage signature corre-
sponded with clinicopathologic characteristics of DCIS
similar to those found in IBC, namely higher grade and
negative hormone receptor status. Such studies emphasize
the role of stroma in breast cancer progression and outcome
prognosis and point to the need for similar studies
evaluating stromal gene expression changes at stages
preceding invasive cancer to identify signatures that may
influence transition from benign to invasive disease.
Analysis of transcriptional profiles of epithelial tissue
derived from ADH, DCIS, and invasive cancer revealed
broad similarities between premalignant and malignant
disease, suggesting a common clonal origin of the different
stages of benign disease [9]. Moreover, most of the
alterations were observed in ADH and persisted through
DCIS and IBC, supporting the concept that characteristics
necessary for development of IBC are already present in
premalignant lesions. A follow-up study performed to
analyze gene expression in the tumor microenvironment
during breast cancer progression identified a large number
of transcriptional alterations in both the epithelium and in
the stroma in DCIS and IBC as compared to normal tissue,
with the differences suggesting that the majority of the
stromal alterations seem to occur before the DCIS stage
rather than in progression from DCIS to invasive cancer
[56]. These findings suggest that paracrine and endocrine
signaling, rather than cell-cell interactions, may be the main
394 J Mammary Gland Biol Neoplasia (2010) 15:389–397factors influencing stromal changes, as the basement
membrane in DCIS is mostly uninterrupted [56, 57].
Further supportingthe importanceofstromainprogression
ofDCIStoIBC,anothertranscriptionalprofilingstudyofcells
from either pure DCIS, the in situ component of DCIS-IBC or
IBC suggested that the molecular changes in the epithelial
cells occurred before the morphological alterations associated
with progression [58, 59]. One of the proposed explanations
of this observation is that the transition from in situ to
invasive carcinoma strongly depends on the signals from
myoepithelial cells, fibroblasts and myofibroblasts. That the
microenvironment is a key mediator of disease progression is
also in line with previous findings suggesting that the most
dramatic transcriptional alterations occur along with devel-
opment of DCIS, and that fewer alterations are found in the
DCIS to IBC transition [56]. Also supporting the concept
that the epithelial cells of DCIS and IBC are very similar in
their gene expression characteristics, a recent study has
demonstrated that the MCF10DCIS cells are able to
spontaneously progress into IBC-like cells, although normal
myoepithelial cells are able to block this progression [31].
Allinen et al. performed the first gene expression
profiling study of subtypes of stromal cells from normal,
DCIS and IBC samples [29]. They used a cell type-specific
purification procedure based on distinct cell surface
markers and magnetic bead separation methods and
performed serial analysis of gene expression (SAGE) to
identify dramatic changes in the microenvironment of DCIS
and IBC as compared to normal tissue. Myoepithelial cells
and myofibroblasts exhibited the most substantial transcrip-
tional alterations, including many genes encoding secreted
and cell surface proteins. Although gene expression
changes were found in all cell types, genetic alterations,
analyzed using single nucleotide polymorphism (SNP)
arrays, were only detected in epithelial cancer cells, which
suggested that the underlying processes were likely due to
epigenetic regulation rather than genetic mutations. In
agreement with these conclusions, DNA methylation
profiling studies provided evidence of consistent epigenetic
alterations in stromal cells when assessing luminal epithe-
lial, myoepithelial, and fibroblast cells from normal
mammary tissue, DCIS, and IBC [60], or of epithelial and
stromal cells from HER2 positive cancers [61]. The
challenge now is to identify the specific signals that lead
to activation of the stroma, how the epigenetic effects are
induced, and how they are maintained.
Future Directions
Transcriptional profiling has proved a powerful tool for
identifying disease categories or processes associated with
disease progression, and critical information has been
obtained when applied to stroma derived from patients with
IBC ortostromal componentsofpatientswithDCIS.A major
gap in our knowledge is the identification of the stromal
factors that control transition from benign disease to carcino-
mainsituandontoinvasivedisease,whichwillrequireuseof
clinical cohorts of patients with benign disease for which
clinical outcome is known. Of course, validation of candidate
processes involved in disease progression will require
experimental systems that model the relevant transitions.
Studies of progression from DCIS to invasive disease have
been facilitated by the use of well characterized cell lines, in
particular the MCF10A series [62, 63] which provides a tool
to study molecular changes that occur at the different stages
of breast cancer development from benign to atypical
hyperplasia, through carcinoma in situ, and on to malignant
c e l l sa b l et of o r mt u m o r sw i t hm e t a s t a t i cc a p a b i l i t i e s .T h e
cell series originated in breast tissue obtained from a woman
with extensive fibrocystic disease [64, 65], and was used to
create a model series of derived cell lines including
premalignant benign proliferating cells with potential for
neoplastic progression (MCF10AT lines) [66, 67], ductal
carcinoma in situ (MCF10DCIS.com) [68] and invasive
carcinoma (MCF10CA1 lines) [63]. MCF10DCIS.com cells
in particular have been employed to model the DCIS to
invasive cancer transition; similar modeling of the atypia to
DCIS (and invasive cancer) transition may be possible using
MCF10AT lines, or new cell lines may be developed from
patients with benign disease. The specific role of stromal
signals in these processes may be investigated using recently
developed humanization models in which cleared fat pads of
immunocompromised mice are populated with human
stromal cells prior to epithelial cell implantation [69–72].
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